How long does durvalumab infusion usually take?

Durvalumab/Durvalumab is an immune checkpoint inhibitor that targets programmed death ligand-1 (PD-L1) and is widely used to treat a variety of malignant tumors including locally advanced non-small cell lung cancer (NSCLC), small cell lung cancer and bladder cancer. In terms of clinical administration, durvalumab is usually administered by intravenous infusion, and its recommended standard infusion time is approximately 60 minutes. This time is set based on multiple clinical trial data and pharmacokinetic characteristics. The purpose is to ensure the efficacy of the drug while reducing the patient's risk of infusion-related adverse reactions.

In specific operations, patients generally receive an infusion of 10 mg/kg once every two weeks, or a fixed dose of 1,500 mg once every four weeks according to the latest updated dosing schedule. Regardless of the dosing regimen used, the standard 60-minute infusion time is the recommended value based on clinical consensus. Of course, in actual operation, the infusion time may fluctuate slightly due to individual differences, the volume of the drug after dilution, the condition of the intravenous access, and the operating specifications of the medical institution. If the patient has no infusion reaction during early administration, some clinical practices may consider shortening the infusion time to 30 minutes, but this requires strict monitoring and is based on safety assessment.

In addition, the medical team usually conducts a thorough assessment before durvalumab infusion, such as checking vital signs, confirming whether there is a history of infusion allergy, and recommends monitoring the patient during and shortly after the infusion to promptly identify and deal with potential adverse reactions. It is worth mentioning that with the widespread application of immunotherapy in tumor treatment, optimization of the infusion experience has become a key link in improving patient compliance and treatment continuity. Therefore, understanding and rationally arranging the infusion time of durvalumab is of great significance to achieve the dual guarantee of therapeutic effect and patient comfort.

Reference materials:https://www.imfinzi.com/